StockNews.com Upgrades Becton, Dickinson and (NYSE:BDX) to Buy

Becton, Dickinson and (NYSE:BDXGet Rating) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Saturday.

A number of other brokerages also recently issued reports on BDX. Argus upped their price target on Becton, Dickinson and from $275.00 to $310.00 in a report on Monday, February 28th. Piper Sandler reduced their price objective on Becton, Dickinson and from $265.00 to $255.00 in a research report on Thursday, May 5th. Morgan Stanley upped their price objective on Becton, Dickinson and from $293.00 to $295.00 and gave the company an “overweight” rating in a research report on Monday, April 11th. Wells Fargo & Company upped their price objective on Becton, Dickinson and from $275.00 to $285.00 and gave the company an “equal weight” rating in a research report on Friday, April 1st. Finally, Bank of America initiated coverage on Becton, Dickinson and in a research report on Tuesday, March 1st. They set a “neutral” rating for the company. Six equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and currently has a consensus rating of “Hold” and a consensus price target of $275.63.

Shares of NYSE:BDX opened at $248.44 on Friday. The company has a market cap of $70.82 billion, a P/E ratio of 39.19, a PEG ratio of 3.52 and a beta of 0.64. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.52 and a quick ratio of 1.04. Becton, Dickinson and has a 1 year low of $235.13 and a 1 year high of $280.62. The stock’s fifty day moving average price is $261.03 and its 200-day moving average price is $257.26.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.99 by $0.19. The firm had revenue of $5.01 billion for the quarter, compared to the consensus estimate of $4.78 billion. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the company posted $3.19 earnings per share. On average, sell-side analysts anticipate that Becton, Dickinson and will post 11.19 earnings per share for the current year.

In related news, EVP David Hickey sold 475 shares of the stock in a transaction dated Friday, May 6th. The stock was sold at an average price of $256.00, for a total transaction of $121,600.00. Following the completion of the sale, the executive vice president now owns 3,806 shares in the company, valued at $974,336. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Betty D. Larson sold 14,374 shares of the stock in a transaction dated Friday, February 25th. The stock was sold at an average price of $271.90, for a total value of $3,908,290.60. The disclosure for this sale can be found here. Corporate insiders own 0.50% of the company’s stock.

Several large investors have recently added to or reduced their stakes in BDX. Accel Wealth Management grew its position in shares of Becton, Dickinson and by 100.0% during the fourth quarter. Accel Wealth Management now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 50 shares in the last quarter. Sierra Capital LLC boosted its stake in Becton, Dickinson and by 88.7% during the fourth quarter. Sierra Capital LLC now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the last quarter. Level Financial Advisors Inc. bought a new position in Becton, Dickinson and during the fourth quarter valued at approximately $26,000. Fortis Advisors LLC bought a new position in Becton, Dickinson and during the third quarter valued at approximately $27,000. Finally, Icapital Wealth LLC bought a new position in Becton, Dickinson and during the first quarter valued at approximately $31,000. Hedge funds and other institutional investors own 86.58% of the company’s stock.

Becton, Dickinson and Company Profile (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Stories

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.